Abstract 995P
Background
Our real-world study aimed to assess the current treatment landscape of aHCC in Ontario, Canada.
Methods
This retrospective cohort study used provincial-level databases from Ontario, Canada to identify patients diagnosed with aHCC between April 2010 and March 2019 with follow-up data available until March 2020. De novo stage IV disease and/or receipt of first line (1L) systemic therapy (ST) was used to establish an aHCC diagnosis. Baseline characteristics, treatment patterns, clinical outcomes, health care resource utilization and costs (in 2020 Canadian dollars) were determined.
Results
A total of 7,322 patients were identified using HCC diagnosis codes, of which 802 met the aHCC diagnosis criteria (82% male, median age 66 years). More than half (N=427) received 1L STs (98% sorafenib; <2% lenvatinib), a quarter (N=195) were untreated, and 9% (N=72) were given locoregional therapy without use of ST. Only 4% (N=19) of 1L treated patients were given a 2L treatment. The median time from diagnosis to 1L ST initiation was 2.3 months and median time on 1L ST was 2.4 months. Median overall survival (mOS) from diagnosis was 9.0 months (95% confidence interval [CI]: 7.8-10.3) and 2.7 months (95% CI: 2.3-3.3) for the treated and untreated cohorts, respectively. The mean total cost per 1L treated patient was $49,640, with oral medications as the main cost driver followed by inpatient hospitalizations.
Conclusions
Our study confirmed guarded prognosis of aHCC despite treatments with sorafenib, in keeping with mOS observed in clinical trials. Low uptake of 1L ST and subsequent uptake of 2L underscores high attrition rates likely related to the frailty of aHCC patients and lack of adequate ST options. Future studies will inform whether immunotherapy-based treatments in the latest years will improve ST uptake, attrition rates and health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HOPE Research Centre.
Funding
AstraZeneca Canada Inc.
Disclosure
D. Bosse: Financial Interests, Personal, Financially compensated role: Ipsen, AstraZeneca, Bayer, Pfizer, Bristol-Meyers Squibb, Amgen, Merck, Knight Therapeutics, Eisai. Y. Kim, J. Tieu, S.Z. Wang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. C. Shephard: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18